Results 201 to 210 of about 20,329 (253)

Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL study. [PDF]

Ann Hematol
Röth A, Barcellini W, Anderson Tvedt TH, Miyakawa Y, Kuter DJ, Su J, Jiang X, Hobbs W, Morales J, Shafer F, Weitz IC.   +10 more
europepmc   +1 more source

Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B. [PDF]

EClinicalMedicine
Röth A, Berentsen S, Barcellini W, D'Sa S, Jilma B, Michel M, Weitz IC, Yamaguchi M, Nishimura JI, Vos JMI, Cid J, Storek M, Wong N, Yoo R, Jayawardene D, Srivastava S, Wardęcki M, Shafer F, Lee M, Broome CM.   +19 more
europepmc   +1 more source

Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension. [PDF]

EClinicalMedicine
Röth A, Broome CM, Barcellini W, Jilma B, Hill QA, Cella D, Anderson Tvedt TH, Yamaguchi M, Murakhovskaya I, Lee M, Shafer F, Wardęcki M, Jayawardene D, Yoo R, Msihid J, Weitz IC.   +15 more
europepmc   +1 more source

Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study.

Blood
D'Sa S, Vos JMI, Barcellini W, Wardęcki M, Perrin L, Barker G, Zilberstein M, Storek M, Chow T, Röth A.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cold agglutinin disease

Blood, 2013
AbstractCold agglutinin disease is a rare and poorly understood disorder affecting 15% of patients with autoimmune hemolytic anemia. We reviewed the clinical and pathologic features, prognosis, and management in the literature and describe our institutional experience to improve strategies for accurate diagnosis and treatment.
Paul L, Swiecicki, Livia T, Hegerova, Morie A, Gertz   +2 more
openaire   +4 more sources

Cold Agglutinins and Cold-Agglutinin Disease

Annual Review of Medicine, 1977
Since the original descriptions of cold-reactive antibodies at the tum of the century, this group of antibodies and the diseases associated with their appearance have become the focus of a great deal of interest (1-5). Early investigators recognized that a group of these patients had paroxysmal hemoglobinuria on exposure to cold, and a subgroup of ...
M M, Frank, J P, Atkinson, J, Gadek
openaire   +2 more sources

Cold agglutinin disease

Postgraduate Medicine, 1976
Development of the Coombs test has led to rapid progress in the recognition of various autoimmune hemolytic anemias. Cold agglutinin disease, a relatively rare disorder, occurs in idiopathic and secondary forms, the latter often in association with diseases that alter the immune status.
openaire   +2 more sources

LYMPHOMATOUS NEUROPATHY IN COLD AGGLUTININ DISEASE

Neurology, 2008
Cold agglutinin disease (CAD) is characterized by the production of cold agglutinins (CAs), usually IgMk autoantibodies, causing chronic hemolytic anemia and cold induced acrocyanosis (reported in 90% of cases). CAD has traditionally been classified into a primary type (pCAD) and a secondary type accompanied by malignant disease, most often lymphoma ...
Riva N, Bezzi G, PONZONI , MAURILIO, Epis R, Previtali SC, Cerri F, Nemni R, COMI , GIANCARLO, Quattrini A.   +8 more
openaire   +4 more sources

Peripheral neuropathy in cold agglutinin disease

Muscle & Nerve, 1991
AbstractCold agglutinin disease (CAD) characteristically presents as anemia and cold‐induced rash. We report a man with purpura, anemia, cold agglutinins, and a sensory‐autonomic polyneuropathy. Treatment with corticosteroids and plasma exchange resulted in resolution of the anemia and polyneuropathy.
T D, Thomas, P D, Donofrio, J, Angelo
openaire   +2 more sources

Cold Agglutinin Disease and Cryoglobulinemia

Clinical Lymphoma, 2005
Cold agglutinin disease is a form of direct, extravascular, antiglobulin-positive hemolysis. In vivo, immunoglobulin (Ig) M fixes complement molecules to the red cell membrane. Successive passages through the mononuclear phagocyte system result in loss of red cell membrane.
openaire   +2 more sources